Navigation Links
Ron Johnson Named Co-Lead Counsel in Lawsuits for Men Injured by AndroGel and Testosterone
Date:8/1/2014

Chicago, Illinois (PRWEB) August 01, 2014

As AndroGel lawsuits and testosterone lawsuits continue to be filed across the country, Ronald E. Johnson, Jr. has been appointed as co-lead counsel to represent the men injured by AndroGel and other testosterone medications. Since the Fall of 2013, Ron and his firm, Schachter, Hendy & Johnson, P.S.C. have worked diligently to investigate and prosecute the claims of men who suffered heart attacks, strokes, pulmonary embolisms, and blood clots as a result of taking testosterone. As a result of these efforts, the medical community and public are being made aware of the true risks of taking testosterone.

In January 2014, the U.S. Food and Drug Administration (FDA) announced that it was investigating the safety of testosterone medications and their potential relationship to heart attacks and strokes (http://www.fda.gov/Drugs/DrugSafety/ucm383904.htm). The FDA will hold a conference in September 2014 to address these issues.

The labeling for all testosterone medications was changed and broadened by the FDA on June 19, 2014 concerning the risks of blood clots (http://www.fda.gov/drugs/drugsafety/ucm401746.htm). Prior labeling only warned about blood clots in the legs as a result of polycythemia. The new labeling warns about blood clots in the legs and lungs generally and not as related to any specific condition other than testosterone use.

Lawsuits filed across the nation are being coordinated in a multi-district litigation (In Re: Testosterone Replacement Therapy Products Liability Litigation, 1:14-cv-01748) before Judge Matthew Kennelly in the Northern District of Illinois. As co-lead counsel for all plaintiffs in testosterone lawsuits, Ron will continue to fight for justice for the men and families whose lives have been devastated by the use of testosterone medications.

Read the full story at http://www.prweb.com/releases/testosteronelawsuit/androgelattorney/prweb12066446.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Johnson & Johnson Violated FDA Order to Halt Sales of Transvaginal Mesh
2. Results from study of Mead Johnsons Enfamil® Human Milk Fortifier Acidified Liquid published in Pediatrics
3. The US Drug Watchdog Now Urges Women Who Suffered A Heart Attack Or Stroke After Using Yaz Yasmin Birth Control Pills To Contact The Johnson Law Group Immediately
4. The US Drug Watchdog Now Urges Any Woman Who Used The Birth Control Pills Yaz Or Yasmin And Then Had A Heart Attack Or Stroke To Call The Johnson Law Group----ASAP
5. US Drug Watchdog Now Urges Women Who Used Yaz or Yasmin Birth Control Pills and Had a Heart Attack or Stroke to Call The Johnson Law Group immediately-Get Identified Now
6. US Drug Watchdog Now Urges Yaz Yasmin Birth Control Pill Users Who Suffered a Pulmonary Embolism or a Heart Attack to Call the Johnson Law Group Now-Before Time Runs Out
7. US Drug Watchdog Now Urges Family Members Of A Diabetic Who Died From Bladder Cancer After Using The Diabetes Drug Called Actos To Call The Johnson Law Group Immediately
8. US Drug Watchdog Now Urges Users Of The Diabetes Drug Called Actos To Call The Johnson Law Group if They Have Developed Bladder Cancer-Time Is Of The Essence
9. US Drug Watchdog Now Urges Yaz Yasmin Birth Control Pill Users Who Suffered a Stroke, Blood Clots, or a Heart Attack to Call the Johnson Law Group for a Legal Review
10. US Drug Watchdog Now Urges Any US Citizen Who Used the Diabetes Drug Called Actos and Then Developed Bladder Cancer To Contact The Johnson Law Group For A Legal Review
11. US Drug Watchdog Now Fears Most Women Never Heard About Yaz or Yasmin Birth Control Pill Side Effects and They Urge to Victims to Call the Johnson Law Group-Get Help Now
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, ... relations, content marketing, social media management, corporate communications, SEO and cause marketing, is ... and in nearby New Hampshire, Massachusetts and Canada, Rosica will focus on expanding ...
(Date:2/23/2017)... ... 2017 , ... Pink Pig Publishing LLC announces the launch ... the world from different perspectives. By providing a place for people of all ... empathy, and find greater happiness. , "Our approach to structuring content is ...
(Date:2/23/2017)... RI (PRWEB) , ... February 23, 2017 , ... ... today a new partnership with the Rhode Island Consortium for Autism Research and ... an opportunity for children with autism spectrum disorder (ASD) to see films in ...
(Date:2/23/2017)... ... February 23, 2017 , ... Curemark, LLC announced today that the ... CM-AT in children aged 3-8 with Autism, is now enrolling at three new sites. ... across the United States. , “There are currently no approved drugs that address ...
(Date:2/22/2017)... Setauket, New York (PRWEB) , ... February 22, ... ... main floor entrance and lobby of a new healthcare contact center in Georgia, ... results. , One of the nation’s largest healthcare systems recently invested $51 million ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... On Wednesday, February 22, 2017, US ... of nine sectors finished the trading sessions in green, four ... Major US indices were also mixed at the close of ... slightly down by 0.09%; the Dow Jones Industrial Average edged ... closed at 2,362.82, down 0.11%. This Thursday morning, Stock-Callers.com looks ...
(Date:2/23/2017)... , February 23, 2017 Tillotts ... the Berlin office was opened ... Kritikos . The portfolio includes Entocort ® for ... the treatment of ulcerative colitis, and VistaPrep ® ... the Swiss specialty pharmaceutical company focused on the treatment ...
(Date:2/23/2017)... DIEGO , Feb. 23, 2017 ... a clinical-stage oncology drug development company, announces that ... and Drug Administration (FDA) authorizing the initiation a ... therapeutic treatment for pancreatic cancer. MVT-1075 ( 177 ... radioimmunotherapy (RIT). MabVax plans to initiate the phase ...
Breaking Medicine Technology: